BioLineRx Ltd.
BLRX
$2.75
-$0.32-10.42%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -95.92% | -42.09% | 1.19% | 91.68% | 502.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -95.92% | -42.09% | 1.19% | 91.68% | 502.92% |
| Cost of Revenue | -97.52% | -8.55% | 16.10% | 52.36% | 150.89% |
| Gross Profit | -95.17% | -57.32% | -7.00% | 122.77% | 1,675.90% |
| SG&A Expenses | -89.41% | -72.40% | -57.17% | -32.80% | -6.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -76.16% | -54.24% | -41.19% | -22.82% | 0.63% |
| Operating Income | 46.29% | 63.83% | 61.94% | 57.08% | 55.45% |
| Income Before Tax | 78.03% | 85.05% | 74.03% | 93.09% | 84.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 78.03% | 85.05% | 74.03% | 93.09% | 84.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 87.26% | 85.05% | 74.03% | 93.09% | 84.79% |
| EBIT | 46.29% | 63.83% | 61.94% | 57.08% | 55.45% |
| EBITDA | 35.55% | 68.65% | 68.41% | 63.61% | 63.62% |
| EPS Basic | 96.00% | 87.78% | 77.89% | 90.94% | 88.17% |
| Normalized Basic EPS | 100.00% | 90.41% | 76.82% | 92.14% | 88.83% |
| EPS Diluted | 96.00% | 87.78% | 77.89% | 90.94% | 88.17% |
| Normalized Diluted EPS | 100.00% | 90.41% | 76.82% | 92.14% | 88.83% |
| Average Basic Shares Outstanding | 105.70% | 86.37% | 65.32% | 47.44% | 24.35% |
| Average Diluted Shares Outstanding | 105.70% | 86.37% | 65.32% | 47.44% | 24.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |